Labcorp Holdings saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 63 to 71.
Can You Really Time The Stock Market?
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Labcorp Holdings can continue to show renewed price strength and clear that threshold.
While it's not currently an ideal time to invest, see if the stock is able to form a base and break out.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 4% to 5%. Revenue rose from 7% to 10%. Look for the next report on or around Apr. 29.
Labcorp Holdings earns the No. 11 rank among its peers in the Medical-Services industry group. Option Care Health, Hims & Hers Health and Quest Diagnostics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
